[link|133|Dainippon Sumitomo Pharma homepage]is an Osaka-based company. It was formed in 2005, from Dainippon Pharmaceuticals (founded in 1897), and from Sumitomo Pharmaceuticals (founded in 1984). The portfolio comprises drugs for diabetes and cardiovascular diseases, therapeutic drugs covering a wide range of CNS diseases from schizophrenia to Parkinson’s disease, anxiety disorders and epilepsia, and drugs for other areas such as bone, inflammation and allergic disorders as well as cancers and infectious diseases. Invested capital is 22,4 billion Yen (178 million €). Sales in FY 2009 were 296,3 billion Yen (~2,4 billion €), with ~7500 employees (consolidated). Representative Director and Chairman of the Board of Directors is Mr Kenjiro MIYATAKE, Representative Director, President and CEO is Mr Masayo TADA.
[link|134|Dainippon Sumitomo Pharma profile]